ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > FGF R2 (IIIc)

FGF R2 (IIIc)

概要

Name:Fibroblast growth factor receptor 2
Target Synonym:EC:2.7.10.1,EC 2.7.10,BEK,K-sam,KGFR,FGFR2,Fibroblast Growth Factor Receptor 2,Keratinocyte Growth Factor Receptor,Bacteria-Expressed Kinase,Protein Tyrosine Kinase, Receptor Like 14,BEK Fibroblast Growth Factor Receptor,Craniofacial Dysostosis 1,Jackson-Weiss Syndrome,Pfeiffer Syndrome,Crouzon Syndrome,CD332 Antigen,EC 2.7.10.1,FGFR-2,BFR-1,CD332,BBDS,CEK3,ECT1,TK14,TK25,CFD1,KSAM,JWS,Receptor, Fibroblast Growth Factor, Type 2
Number of Launched Drugs:7
Number of Drugs in Clinical Trials:27
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
FGC-H5225 Human Human FGF R2 (IIIc) protein, His Tag (MALS verified)
FGC-H5225-structure
FGC-H5225-sds
ACRO Quality

生物活性データの一部

FGC-H5225-MALS-HPLC
Human FGFR2 (IIIc), His Tag (Cat. No. ) MALS images

The purity of Human FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) is more than 90% and the molecular weight of this protein is around 45-55 kDa verified by SEC-MALS.

Bioactivity-ELISA
Human FGFR2 (IIIc), His TagHuman FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) ELISA bioactivity

Immobilized Human FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Tag Free with a linear range of 0.04-1.25 μg/mL (Routinely tested).

FGC-H5225-ELISA
Human FGFR2 (IIIc), His TagHuman FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) ELISA bioactivity

Immobilized Human FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Tag Free with a linear range of 0.04-1.25 μg/mL (Routinely tested).

Synonym Name

FGF R2 (IIIc),FGFR2B,FGFR2

Background

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Erdafitinib 890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210 Approved Astex Pharmaceuticals Inc Balversa United States Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Lymphoma, Non-Hodgkin; Osteosarcoma; Sarcoma, Ewing; Prostatic Neoplasms; Breast Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Bile Duct Neoplasms; Urologic Neoplasms; Carcinoma, Squamous Cell; Glioma; Sarcoma; Lymphoma; Carcinoma, Neuroendocrine; Neoplasms, Neuroepithelial; Carcinoma, Hepatocellular; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Medulloblastoma; Ependymoma; Bone metastases; Rhabdomyosarcoma; Hematologic Neoplasms; Carcinoma; Rhabdoid Tumor; Hepatoblastoma; Esophageal Neoplasms; Stomach Neoplasms; Solid tumours; Wilms Tumor; Neoplasms; Glioblastoma; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Neuroblastoma; Histiocytosis, Langerhans-Cell Details
Futibatinib TAS-120 Approved Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd LYTGOBI United States Cholangiocarcinoma Taiho Oncology Inc 2022-09-30 Biliary Tract Neoplasms; Solid tumours; Bone Marrow Neoplasms; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Endometrial Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Carcinoma, Non-Small-Cell Lung Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Glioma; Bile Duct Diseases; Peritoneal Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Urologic Neoplasms; Hepatic Insufficiency; Thyroid Neoplasms; Sarcoma, Alveolar Soft Part; Fallopian Tube Neoplasms; Nasopharyngeal Carcinoma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Gallbladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Osteoma; Melanoma; Neoplasms; Ovarian Neoplasms; Drug-Related Side Effects and Adverse Reactions; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Thoracic Neoplasms; Esophageal Neoplasms; Leiomyosarcoma; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Lung Diseases, Interstitial; Neuroendocrine Tumors; Liver Diseases; Sarcoma; Medullary thyroid cancer (MTC) Details
Pemigatinib INCB-054828; INCB-54828; IBI-375 Approved Incyte Corp Pemazyre, 伯坦, 达伯坦 United States Cholangiocarcinoma Incyte Corp 2020-04-17 Breast Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Glioma; Lung Neoplasms; Lymphoma; Colitis, Ulcerative; Bile Duct Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Cholangiocarcinoma; Translocation, Genetic; Bone Marrow Neoplasms; Multiple Myeloma; Urinary Bladder Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Myeloproliferative Disorders; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Biliary Tract Neoplasms; Solid tumours Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef United States Idiopathic Pulmonary Fibrosis Boehringer Ingelheim Gmbh 2014-10-15 Carcinoma, Squamous Cell; Sarcoma; Prostatic Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Colorectal Neoplasms; Peritoneal Neoplasms; Astrocytoma; Genital Neoplasms, Female; Hepatic Insufficiency; Silicosis; Gliosarcoma; Breast Neoplasms; Lung Neoplasms; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Adenocarcinoma; Glioblastoma; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Carcinoma, Renal Cell; Carcinoid Tumor; Endometrial Stromal Tumors; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Ovarian Neoplasms; Scleroderma, Systemic; Neoplasms; Small Cell Lung Carcinoma; Lung Diseases, Interstitial; Mesothelioma; Pulmonary Fibrosis; Multiple Myeloma; Asbestosis; Oligodendroglioma; Neuroendocrine Tumors Details
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance United States Colorectal Neoplasms Bayer Healthcare Pharmaceuticals Inc 2012-09-27 Esophageal adenocarcinoma; Osteosarcoma; Sarcoma, Ewing; Bile Duct Neoplasms; Peritoneal Neoplasms; Bone Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Fallopian Tube Neoplasms; Lung Neoplasms; Thyroid Neoplasms; Sarcoma; Leukemia, Myeloid, Acute; Thymoma; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Somatostatinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Solid tumours; Liver Neoplasms; Carcinoid Tumor; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Islet Cell; Insulinoma; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Glucagonoma; Carcinoma, Adenoid Cystic; Adenoma; Gastrinoma Details
Lenvatinib Mesylate ER-203492-00; E-7080; MK-7902 Approved Eisai Co Ltd Lenvima, Lenvima/Kisplyx, 乐卫玛, Kisplyx United States Thyroid Neoplasms Eisai Inc 2015-02-13 Carcinoma, Adenoid Cystic; Thyroid Cancer, Papillary; Melanoma; Paraganglioma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Thyroid Neoplasms; Endometrial Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Breast Neoplasms; Osteosarcoma; Solid tumours; Adenocarcinoma, Follicular; Liver Diseases; Neuroendocrine Tumors; Thyroid Carcinoma, Anaplastic; Kidney Diseases; Adenocarcinoma of Lung; Neoplasms; Esophageal Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Pheochromocytoma; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Bemarituzumab FPA-144 Phase 3 Clinical Five Prime Therapeutics Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Digestive System Neoplasms; Carcinoma, Squamous Cell; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms Details
Infigratinib BGJ-398; NVP-BGJ398 Phase 3 Clinical Novartis Pharma Ag Papillomavirus Infections; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Glioma; Oropharyngeal Neoplasms; Gastrointestinal Stromal Tumors; Breast Neoplasms; Cholangiocarcinoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Solid tumours; Nasopharyngeal Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Achondroplasia; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Biliary Tract Neoplasms Details
Rogaratinib BAY-1163877 Phase 3 Clinical Bayer AG Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Non-Small-Cell Lung Details
Fexagratinib AZD4547; AZD-4547; ABSK-091; ABSK091 Phase 3 Clinical Astrazeneca Plc Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal adenocarcinoma; Endometrial Neoplasms; Lymphoma; Uterine Neoplasms; Multiple Myeloma; Glioma; Thyroid Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma; Stomach Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Carcinoma, Renal Cell; Solid tumours; Gastrointestinal Diseases; Neoplasms; Carcinoma, Transitional Cell; Skin Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Urinary Bladder Neoplasms Details
CPL-304110 CPL-304110; CPL-304-110 Phase 1 Clinical Celon Pharma Sa Stomach Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Cholangiocarcinoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
Efruxifermin AKR-001; AMG-876; EFX; Fc-FGF21(RGE) Phase 3 Clinical Amgen Inc Non-alcoholic Fatty Liver Disease; Diabetes Mellitus Details
Lirafugratinib RLY-4008 Phase 2 Clinical Relay Therapeutics Inc Cholangiocarcinoma; Translocation, Genetic Details
Tasurgratinib E-7090 Phase 2 Clinical Eisai Co Ltd Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency Details
LY-2874455 LY-2874455 Phase 1 Clinical Eli Lilly And Company Neoplasms; Leukemia, Myeloid, Acute Details
Lucitanib S-80881; AL-3810; CO-3810; E-3810; S-80881-2 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
ABSK-121 ABSK121-NX; ABSK121 Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours Details
Nintedanib Solution for Inhalation AP02; AP-02 Phase 1 Clinical Avalyn Pharma Inc Idiopathic Pulmonary Fibrosis Details
HMPL-453 HMPL-453 Phase 2 Clinical Hutchison Medipharma Ltd Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma Details
TT-00434 TT-00434 Phase 1 Clinical TransThera Sciences (Nanjing) Inc Solid tumours; Urinary Bladder Neoplasms Details
TYRA-200 TYRA200; TYRA-200 Phase 1 Clinical Tyra Biosciences Inc Biliary Tract Neoplasms; Solid tumours; Cholangiocarcinoma; Bile Duct Neoplasms Details
Gunagratinib ICP-192 Phase 2 Clinical Beijing Tiancheng Pharmaceutical Technology Co Ltd Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms Details
BPI-17509 BPI-17509 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours Details
KIN-3248 KIN-3248; KIN-003 Phase 1 Clinical Kinnate Biopharma Inc Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma Details
Derazantinib ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 Phase 2 Clinical Arqule Inc Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular Details
Sprifermin rhFGF-18; trFGF-18; FGF-18; zFGF-5; Zfgf5; AS-902330 Phase 2 Clinical Zymogenetics Inc Cartilage Diseases; Knee Injuries; Osteoarthritis, Knee Details
Zoligratinib CH-5183284; FF-284; Debio-1347 Phase 2 Clinical Chugai Pharmaceutical Co Ltd Solid tumours; Breast Neoplasms Details
ODM-203 ODM-203 Phase 1 Clinical Orion Corp Solid tumours Details
Alofanib RPT-835 Phase 1 Clinical Russian Pharmaceutical Technologies Llc Stomach Neoplasms Details
HH185 3D-185; 3-D185; HH-185; 3D185 Phase 2 Clinical ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc Solid tumours; Cholangiocarcinoma Details
ABSK-061 ABSK061 Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours Details
SC-0011 SC-0011 Phase 1 Clinical Shijiazhuang Zhikang Hongren New Drug Development Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totopphone